20. Other financial assets

Other financial assets are as follows:

	Dec. 31, 2006		Dec. 31, 2007
€ million	Total	of which current	Total	of which current
Loans and receivables	450	165	347	126
of which pertaining to associates	3	2	1	-
Available-for-sale financial assets	395	38	325	7
of which debt instruments	66	28	59	5
of which equity instruments	329	10	266	2
Held-to-maturity financial investments	172	32	179	9
Receivables from forward commodity contracts	137	32	246	38
Receivables from other derivative financial instruments	280	121	339	154
Receivables under lease agreements	61	13	26	1
Total	1,495	401	1,462	335

In 2007, impairment losses of €9 million (2006: €2 million) were recognized on loans and receivables and an impairment charge of €27 million (2006: €20 million) was recognized on available-for-sale financial assets. No unimpaired other financial assets were overdue on the closing date.

Available-for-sale financial assets include equity instruments in the amount of €86 million (2006: €98 million) whose fair value could not be determined from a stock exchange or other market price or by discounting reliably determined future cash flows. These equity instruments are recognized at cost.

Further information on the accounting for receivables from derivative financial instruments is given in Note [30].

Receivables from leasing agreements relate to finance leases where Bayer is the lessor and the lessee is the economic owner of the leased assets. The following table provides a breakdown of these payments into a lease and an interest component, together with their due dates:

Dec. 31, 2006
€ million	Lease payments	Interest component	Receiv- ables under finance leases
2007	15	2	13
2008	15	2	13
2009	5	2	3
2010	4	1	3
2011	3	1	2
2012 or later	29	2	27
Total	71	10	61

Dec. 31, 2007
€ million	Lease payments	Interest component	Receiv- ables under finance leases
2008	2	1	1
2009	2	1	1
2010	2	1	1
2011	2	1	1
2012	1	1	-
2013 or later	23	1	22
Total	32	6	26